Analysis of the Serum Marker EPCA-2 in Prostate Cancer

前列腺癌血清标志物EPCA-2分析

• 批准号: 7919419
• 负责人: ROBERT GETZENBERG
• 金额: $ 25.24万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7919419
• 关键词: Address; Antigens; Benign Prostatic Hypertrophy; Biochemical; Biological Assay; Biological Markers; Biopsy; Cell Nucleus; Data; Diagnosis; Disease; Early Diagnosis; Early treatment; Elements; Gland; Gleason Grade for Prostate Cancer; Goals; Hospitals; Human; Invaded; Malignant Neoplasms; Malignant neoplasm of prostate; Monitor; Morbidity - disease rate; Nuclear; Nuclear Matrix; Nuclear Structure; Operative Surgical Procedures; Patient Care; Patients; Population; Process; Progressive Disease; Prostate; Prostate-Specific Antigen; Proteins; Proteomics; Rattus; Recurrence; Recurrent disease; Reporting; Reproduction spores; Role; Sampling; Screening procedure; Serum; Serum Markers; Specificity; Staging; Subcellular Fractions; Test Result; Testing; Time; Tissues; Transgenic Mice; Translations; cancer cell; clinically significant; effective therapy; follow-up; killings; men; men' s group; migration; mouse model; prostatitis; success

Despite the success of using PSA as a prostate cancer biomarker for more than 25 years, it is clear that we need a marker that is both specific for the disease and that can differentiate the disease with the potential to kill from that which will not result in clinical significance. Utilizing proteomics focused on the nuclear matrix, we have identified alterations associated with prostate cancer. One such change, EPCA-2 is the focus of this application. The assay which detects serum levels of EPCA-2 has been shown to be specific for the disease and is able to discriminate between disease inside the prostate at the time of surgery and disease which has spread outside of the gland. The hypothesis being evaluated in this project is that EPCA-2 can serve as a prostate cancer biomarker that can differentiate between aggressive and non-aggressive prostate cancer. The goal of this project is translation of prostate cancer biomarkers (e.g. EPCA-2) into patient care for prostate cancer within a multi-institutional SPORE platform. The following specific aims are proposed to address this hypothesis: 1) to determine the ability of EPCA-2 to differentiate between populations of Gleason score 6, 7 and 8-10 in a population of Johns Hopkins Hospital patients as well as in an inter-SPORE study; 2) to analyze if serum EPCA-2 levels can identify which men, who at the time of surgery have Gleason 7 prostate cancer and a minimum of 10 year follow-up, have biochemical recurrence (PSA) from those with non-recurrent disease. These studies will consist of sample sets both from Johns Hopkins as well as other available SPORE sample sets; and 3) to begin to determine the functional role of the EPCA-2 protein in the disease process as well as the mechanism by which it is released into the serum.

尽管使用PSA作为前列腺癌生物标志物已成功超过25年，但很明显， 需要一种标志物，既对疾病特异，又能区分疾病， 不会导致临床意义的药物。利用专注于核基质的蛋白质组学， 我们已经发现了与前列腺癌相关的改变。EPCA-2是其中一个变化， 这个应用程序。检测EPCA-2血清水平的测定已显示对以下疾病具有特异性： 并且能够区分手术时前列腺内的疾病和 已经扩散到腺体外了在这个项目中评估的假设是，EPCA-2可以 作为前列腺癌的生物标志物，可以区分侵袭性和非侵袭性 前列腺癌该项目的目标是将前列腺癌生物标志物（例如EPCA-2）转化为 在多机构SPORE平台内为前列腺癌患者提供护理。具体目标如下： 提出解决这一假设：1）确定EPCA-2区分 在约翰霍普金斯医院的患者群体中以及 一项孢子间研究; 2）分析血清EPCA-2水平是否可以识别哪些男性，谁在怀孕时， 手术有Gleason 7前列腺癌和至少10年随访，有生化复发 (PSA)非复发性疾病的患者。这些研究将包括样本集都来自约翰 霍普金斯以及其他可用的SPORE样本集;以及3）开始确定 EPCA-2蛋白在疾病过程中的作用以及它释放到血清中的机制。